Bicara Therapeutics names two new directors as Mazumdar-Shaw exits board

Bicara Therapeutics Inc. (Nasdaq: BCAX) said in a July 28, 2026 8-K that it appointed Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors.

Kiran Mazumdar-Shaw resigned from the board and her seat on the Nominating and Corporate Governance Committee on July 23, 2026, effective July 28, 2026.¹ The company said her decision to resign was not the result of any disagreement with the company over its operations, policies or practices.¹

Bender was appointed as a Class I director to hold office until Bicara's 2028 annual meeting of stockholders, and Oliger was appointed as a Class II director to hold office until the 2029 annual meeting, both effective July 28, 2026.¹ The board determined that each is independent under Nasdaq Global Market listing standards.¹ Bicara also increased its authorized board size from nine to ten directors.¹

Bender most recently served as CEO of Day One Biopharmaceuticals from September 2020 to April 2026. During his tenure he led the company's evolution into a commercial-stage oncology firm, including the approval and launch of OJEMDA for pediatric low-grade glioma and its roughly $2.5 billion acquisition by Servier in 2026.¹

Oliger previously ran Genentech's oncology business. From 2017 to 2020 she served as Senior Vice President, Business Unit Head for Oncology, overseeing a portfolio of 15 products that generated more than $13 billion in U.S. revenue, and led launches in lung cancer, breast cancer, chronic lymphocytic leukemia and other indications.¹

Both new directors will receive an initial non-qualified stock option award of 38,950 shares plus standard cash compensation under Bicara's director pay policy.¹ The board also formed a new Launch Readiness Committee, chaired by Kate Haviland, with Bender and Oliger as members, to advise on commercialization strategy and launch readiness.¹